Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC)

•Early BRCA testing is crucial and enables personalized treatment approach.•BRCA mutation analysis is essential and should be utilized at the time of diagnosis.•Single-agent PARP inhibitors seem most beneficial in BRCA mutations or HRD.•Evidence suggests bevacizumab or niraparib-alone benefits for HRD-negative patients.•HRD-tailored treatment should be explored further.